EQT Private Equity announced a recommended all-cash public takeover offer for QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) on October 21, 2026 at €46.50 per share. The transaction values QIAGEN at approximately €10.8Bn in enterprise value, or approximately $12.1Bn at current exchange rates, including approximately $1.1Bn of net debt. The price represents a premium of approximately 40.3% to the XETRA close of €33.15 on July 8, 2026, the last trading day before market reports of takeover interest, and a premium of approximately 46.9% to the three-month VWAP on XETRA of €31.66 up to that date. QIAGEN’s boards have unanimously approved the Business Combination Agreement and support the transaction.

The structure leaves relatively little optionality on the table. EQT has secured committed equity and debt financing to cover the full offer consideration and related transaction costs, and the offer is not subject to any financing condition. The bidding vehicle is Crown NL Bidco B.V., indirectly controlled by the EQT XI fund, with indirect participations from Luxinva S.A., a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), alongside CPP Investment Board Europe Inc., a wholly-owned subsidiary of Canada Pension Plan Investment Board (CPP Investments). The offer is proceeding under the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG) and is subject to BaFin approval of the Offer Document, even though QIAGEN remains a Netherlands-based holding company.

The Path to Completion

The minimum acceptance threshold is a majority of outstanding share capital, a comparatively modest bar that probably reduces blocking risk. Beyond acceptances, closing depends on certain EGM resolutions, including approval of the Post-Closing Measures, together with a separate Implementation Decision by the QIAGEN Boards, merger control and foreign investment clearances, and further conditions to be set out in the Offer Document. Non-tendering shareholders would receive a cash distribution per share equal to the Offer Price less applicable withholding taxes, and the Frankfurt and NYSE listings are to be terminated. The Implementation Decision follows approval of the Post-Closing Measures by at least 80.0% of votes cast, failing which the QIAGEN Boards may still proceed if they determine it is in QIAGEN’s best interest, subject to the support of a substantial majority of the shareholder base.

The Offer Document is expected to be published following BaFin clearance, at which point the acceptance period begins, and a U.S. tender offer is expected to commence the same day with a Schedule TO filed with the SEC. Closing is currently expected in mid-2027, roughly eight months from announcement. If closing has not occurred within ten months of announcement because required regulatory approvals remain pending, QIAGEN may elect to pay shareholders an interim dividend of up to $0.47 per share, and that amount would not be deducted from the Offer Price.

Why Private Ownership

The rationale offered by both sides centers on freedom of action rather than cost. Chief Executive Officer Jonathan M. Pratt observed that under private ownership the company can move faster and have greater freedom, and Chief Financial Officer Roland Sackers pointed to EQT’s support and resources strengthening QIAGEN’s ability to pursue new opportunities. Stephen H. Rusckowski, Chairman of the Supervisory Board, framed the offer as providing compelling value while positioning QIAGEN for its next phase of development. Taken together, those statements likely describe a gap between the investment the company wanted to make and what public market investors would tolerate in reported results.

That gap is a familiar one in life science tools and diagnostics. Demand across much of the sector normalized sharply after the pandemic-era testing cycle, and the subsequent reset in growth rates has left sector trading multiples well below their 2021 levels. Companies in that position often face a choice between protecting near-term margins and funding menu expansion, instrument placements or bioinformatics capability, and public shareholders have more often rewarded the former. Private ownership does not remove that trade-off, but it does change who adjudicates it and over what horizon.

QIAGEN describes itself as a global leader in Sample to Insight solutions, serving more than 500,000 customers across Life Sciences and Molecular Diagnostics with about 5,400 employees in more than 35 locations. EQT’s commitments under the Business Combination Agreement appear designed to address the predictable concerns about sponsor ownership, covering strategy, business, key brands, operational footprint, R&D activities, employee arrangements, prudent financing and culture, and the company will continue to operate under the QIAGEN name and brand. With €354.0Bn of assets under management, EQT is among the few sponsors able to fund an equity commitment of this size, and the participation of ADIA and CPP Investments probably reflects a preference for long-duration capital in a business whose economics depend on installed base and consumable pull-through.

Read-Through for the Sector

The transaction is likely to be read as a marker for where sponsor appetite in healthcare now sits. Take-private activity has concentrated on businesses with recurring revenue, installed-base economics and defensible positions in regulated markets, and QIAGEN’s sample and assay franchises fit that description reasonably well. Secondary press reports in July named EQT, KKR and Advent as potential buyers, and QIAGEN had reviewed strategic options earlier in the year.

For listed peers, the more immediate consequence may be valuation rather than competition. A take-private at a 40.3% premium to the undisturbed price establishes a reference point that shareholders in comparable businesses are likely to cite, particularly where multiples have stayed depressed. The release does not mention a break fee, termination fee, go-shop or matching rights, so the deal protections, if any, may only become visible when the Offer Document is published.

What Shareholders Are Being Asked

QIAGEN shareholders are being asked to accept certainty of value now in exchange for participation in whatever the next phase of development produces. The premium on offer is substantial by the standards of large-cap European takeovers, and the absence of a financing condition removes a category of execution risk that has complicated other sponsor-led bids. The principal open questions appear to be regulatory rather than commercial, and the interim dividend mechanism suggests the parties have already allowed for some delay.

Our reading is that this transaction says less about QIAGEN’s difficulties than about the cost of funding a long-cycle instrument and consumables business under quarterly disclosure. EQT, ADIA and CPP Investments appear to be underwriting broadly the strategy the company was already pursuing, on a timetable that public markets were previously pricing at a discount. If the offer completes on the terms announced, the sector may see further approaches of similar shape, combining well-capitalized consortia, premiums anchored to pre-speculation prices and commitments on footprint and R&D. For owners of listed diagnostics assets, that is worth factoring into how they think about standalone value.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial